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Summary
Objective: To identify the CD44-receptor-mediated effects of 5–7×105 MW hyaluronan (HA, Hyalgan®) on cell viability in normal and
damaged human chondrocyte primary cultures isolated from articular cartilage.
Design: Primary cultures of human chondrocytes were established from normal articular biopsies and expanded to the second culture
passage. The dose–response effects of HA on the viability of normal cultures were identified. Chondrocytes were then treated with either
hypoxanthine (2 mM) and xanthine oxidase (20–60 mU), or with activated polymorphonuclear leukocytes (PMNs) to induce injury. Damaged
and control cells were then treated with 5–7×105 HA in the previously identified optimal dose of 0.05 mg/ml. Viability was assessed at specific
time periods for the chemically and PMN-damaged cells. To identify if HA effects were mediated by the CD44 receptor, chondrocytes were
incubated with anti-CD44 antibody at saturating concentrations (5 µg/ml for 100 000 cells) to produce a maximum inhibition of HA binding.
Cells were evaluated using the MTT viability assay, histology, electron microscopy and immunohistochemistry.
Results: Direct addition of HA (optimal dose, 0.5 mg/ml) significantly increased cell survival in normal chondrocyte primary cultures (P<
0.05). Similarly, addition of this same dose of HA to cultures of free radical-damaged chondrocytes, restored the viability to baseline
conditions. Cell viability rates dropped significantly (P<0.05) when CD44 receptor binding was inhibited, indicating that cell growth was
mediated by the CD44 receptor.
Conclusions: HA (0.5 mg/ml of 5–7×105) significantly increased the viability of normal human chondrocytes in primary culture and restored
cell viability to near normal levels after oxidative cell injury.
© 2003 OsteoArthritis Research Society International. Published by Elsevier Science Ltd. All rights reserved.
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Introduction
Native hyaluronan (HA) is a large glycosaminoglycan
that comprises repeating disaccharide subunits of
N-acetylglucosamine and D-glucuronic acid. It plays a key
role in the structure and organization of the extracellular
matrix (ECM)1–3, and can be found in most organs and
tissues. A high molecular weight HA molecule is found in
abundance in joint synovial fluid. Its unique rheological
properties render it highly viscous and of great lubricating
capacity: both essential requirements for the integrity of
articular cartilage and the overall mechanical performance
of synovial joints. In diseases of chronic articular inflam-
mation, the concentration and average molecular weight
(MW) of HA have been shown to decrease significantly,
resulting in decreased synovial fluid (SF) viscosity4
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Fig. 1. Effect of HA on chondrocyte viability in culture. Cells were
cultured with and without HA (four concentrations tested: 0, 0.25,
0.5, 0.75, and 1.0 mg/ml). Each column depicts the mean MTT
value of three experiments. HA significantly enhanced cell prolif-
eration at the 0.5 mg/ml dose and at 9 days of culture. Values are
expressed as optical density (OD)±standard deviation (SD). Each
column depicts the mean value of three experiments. Statistical
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and, possibly, in cartilage disruption5,6. These small HA
fragments are unable to bind to CD44, the principal HA
receptor on chondrocytes7,8. This receptor molecule, a type
I transmembrane protein and a member of the cartilage link
protein family, is expressed on the surface of chondro-
cytes9,10, and its binding to HA is essential to both the
adhesive and cell-signaling functions of the ECM7,11–16.
Chondrocytes are known to highly express CD44
Fig. 2. Immunolocalization of CD44 on chondrocyte cell surface at 7 days of culture. The presence of CD44 was determined
immunohistochemically using a monoclonal antibody against CD44. Cells were counterstained with hematoxylin. (a) Cells show a positive
staining for the molecule (red color) (magnification, 400×); (b) negative control.
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receptors, which after their binding to HA, result in in-
creased cell proliferation. This effect has been shown to
be independent of both transforming growth factor (TGF)
and c-myc mRNA17, two supposedly critical mediators of
cartilage metabolism18.
Some studies demonstrated that PMN-generated reac-
tive oxygen radical species (ROS) may be responsible for
the HA fragmentation and ECM disassembly in chronically
inflamed cartilage of osteoarthritic (OA) patients19–22.
Apoptosis has also been recently correlated to the degen-
erative processes of osteoarthritis23. The pharmacological
basis of therapy in osteoarthritis should aim to reduce the
damage caused by oxygen-free radicals and to stimulate
cartilage tissue repair. Intra-articular injection of exogenous
HA has been shown to give relief to OA patients24, and
some HA preparations have recently been approved by the
American Food and Drug Administration (FDA). The thera-
peutic effects of HA are thought to be mediated by in-
creased lubrication of joint SF3, a protective effect against
the cytotoxicity of reactive oxygen species25–27 and/or an
anti-inflammatory effect28.
Several studies have shown that 5–7×105 Da MW HA
preparations (Hyalgan®), which are known to have a
half-life of 17 h in the joint, are equally efficacious as
conventional therapy in the short term, but are of longer
duration of action29–37. An explanation for this ‘long-term’
effect is not forthcoming, but may be related to a positive
effect of HA on chondrocyte survival, resulting ultimately in
cartilage repair.
Since no data on the effect of 5–7×105 Da MW HA
preparations on chondrocyte viability are available, the
present study was undertaken to explore the effect of
Hyalgan on in vitro cultured human chondrocytes, both
untreated and damaged by reactive oxygen-derived toxic
species. Participation of the CD44 HA receptor in this
mechanism was also investigated.
Materials and methods
HYALURONAN
HA preparations were extracted and purified from rooster
comb tissue and had a MW of 5–7×105 Da (Hyalgan®:
FIDIA Research Laboratories, Abano Terme, Italy). Four
concentrations were evaluated for the effect on the viability
of normal chondrocytes in primary culture: 0.25, 0.50, 0.75,
and 1.0 mg/ml. The most effective of these doses was then
chosen for the subsequent study in damaged cells.
HUMAN CHONDROCYTES
Primary cultures of human chondrocytes were estab-
lished from articular biopsies taken from normal, non-
weight bearing articular cartilage during surgery38. Briefly,
finely minced and pooled biopsies were treated with serial
enzymatic digestion: trypsin 0.25%–EDTA 0.02% (Gibco),
testicular hyaluronidase (Sigma) and collagenase type I
(Sigma). The digested material was than resuspended
in complete Ham’s F12 medium supplemented with 10%
fetal calf serum (FCS), 1% penicillin/streptomycin, 1%
l-glutamine, 50 µg/ml l-ascorbic acid (Sigma), 1 ng/ml TGF
β1 (Calbiochem), 1 ng/ml insulin (Sigma), 1 ng/ml epider-
mal growth factor (EGF, Sigma) and 10 ng/ml b-fibroblast
growth factor (bFGF, Calbiochem).
Chondrocytes were expanded for 7 days (two passages).
Medium was changed every other day and the viability of
each cell preparation was tested with trypan blue exclusion.
At confluence, cells were trypsinized, detached from the
plastic dishes and split at a ratio 1:3.
SUPEROXIDE-GENERATING SYSTEM AND CELL DAMAGE
Two superoxide-generating systems were used to induce
cell damage:
(a) Cell monolayers were incubated at 37°C for 30 min
with hypoxanthine (2 mM) and xanthine oxidase (20–
60 mU) in the presence of FeSO4 and EDTA (0.2 mM).(b) Polymorphonuclear leukocytes (PMNs) were isolated
from normal human blood by dextran sedimentation
followed by Ficoll–Hypaque gradient and hypotonic
lysis of erythrocytes. They were then activated by
reaction with formyl–methionyl–leucyl-phenylalanine
peptide (FMLP) and cytochalasin B. PMNs were
seeded on 0.4 µm pore filters that were positioned
inside wells containing cultured chondrocytes. In this
way, the two cells were grown separately, yet within
the same culture environment, communicating and
interacting via their metabolic products.
Cell viability was established by the MTT test (see
subsequent discussion) and by histological examination of
cells.
CELL VIABILITY IN THE PRESENCE OF HA
To evaluate the effects of HA on normal cell viability,
human chondrocytes in standard primary culture conditions
were grown with varying concentrations (0, 0.25, 0.5, 0.75
and 1 mg/ml) of HA (Hyalgan®) in complete Ham’s F12
medium. At various time points (Days 3, 6, 9), samples
were evaluated for viability.
To evaluate the effects of HA on the viability of damaged
cells, chondrocytes were cultured in complete Ham’s F12
Fig. 3. Inhibition of HA binding to chondrocyte CD44 receptor. The
addition of monoclonal anti-CD44 antibodies to chondrocyte cul-
ture medium in the presence of 0.5 mg/ml HA produced a maxi-
mum inhibition of HA binding. Anti-CD44 antibodies also inhibited
normal baseline proliferation of control cell cultures at 9 days. Each
column depicts the mean value of three experiments. Values
are expressed as optical density (OD)±standard deviation (SD).
Statistical analyses; Mann–Whitney U test.
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Fig. 4. Effect of HA on morphology of cells treated with oxygen-free radicals. Human chondrocytes exposed to oxygen radical flux generated
by xanthine oxidase for 30 min: (a) normal human chondrocytes; (b) human chondrocytes exposed to oxygen radical flux with no HA
treatment; and (c) with HA treatment (0.5 mg/ml). In (b) and (c), chondrocytes demonstrated cytoplasmic vacuolization induced by
free-radical damage, whereas nuclear condensation was observed primarily in untreated samples (panel b). Toluidine Blue staining. Original
magnification: 400×.
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medium supplemented as previously described, and
were:
(a) treated with HA (0.5 mg/ml), both at the moment and
immediately after oxidative damage (chemically or
PMN-activated induced) and in all post-injury media
changes. Chemically damaged cells were tested for
viability after 3, 6 and 9 days, and PMN-damaged cells,
after 5 and 10 days.
(b) treated with HA only immediately after chemical oxi-
dative damage. Viability of cell were tested at 3–6–9
days.
Each experiment was performed three times with differ-
ent cartilage samples taken from different subjects.
HA RECEPTOR BINDING INHIBITION
The mediation of HA effects by the CD44 receptor was
tested by receptor-binding inhibition. Human chondrocytes
were incubated with a primary mouse anti-human CD44
monoclonal antibody (AnCell) at saturating concentrations
(5 µg/ml for 100 000 cells) to produce a maximum inhibition
of HA binding.
CELL VIABILITY ASSAY
Viability rates were determined using the MTT-based
(Thiazolyl blue) cytotoxicity test according to the method of
Denizot and Lang39 with minor modifications. This test is
based on mitochondria viability: only functional mitochon-
dria can oxidize an MTT solution, giving a typical blue-violet
end product. Briefly, supernatant was harvested from cul-
ture dishes, 1 ml of MTT solution (0.8 mg/ml) was added
and samples were returned to the incubator (37°C). After
3 h, supernatant was harvested, 1 ml of extraction solution
(10% DMSO in isopropanol) was added, and the samples
were read at 540 nm, with 630–660 nm used as the refer-
ence wavelength. A calibration curve was established.
ELECTRON MICROSCOPY
Cultured chondrocytes were rapidly washed with fresh
medium serum-free at 37°C, rinsed with PBS, pH 7.2, at
room temperature and fixed with 2,5% glutaraldeyde in
0.1 M Na–Cacodilate buffer, pH 7.4, for 24 h at 4°C. After
washing three times (10 min each) with cold buffer, cells
were post-fixed for 20 min at 4°C in 1% OsO4 and rinsed
again with cacodilate buffer. Chondrocytes were then
separated with a rubber and dehydrated in a series of
ascending water–ethanol mixtures (30–100%) prior to
embedding in Epon 812 (Fluka) and polymerizing accord-
ing to standard techniques40. Thin sections were cut with
a Reichter–Jung Ultracut ultramicrotome, collected on
copper grids, stained with 2,5% alcoholic uranyl acetate
and Reynold’s lead citrate, and finally examined in a CM12
Fig. 5. Ultrastructure of cells treated with oxygen free radicals. Human chondrocytes exposed to oxygen radical flux generated by xanthine
oxidase for 30 min: (a) normal human chondrocytes; (b) human chondrocytes exposed to oxygen radical flux with no HA treatment (10 000×);
and (c) with HA treatment (0.5 mg/ml; 8000×). Changes in the cytoplasmic were mainly vacuolization and marked enlargement of the
endoplasmic reticulum, whereas in the nucleus, extensive chromatin condensation was observed. Vacuolization and nuclear damage was
more pronounced in chondrocytes exposed to xanthine oxidase with no HA treatment (panel b).
Fig. 6. HA-mediated recovery of chondrocyte viability when added
to cell culture both at the moment of oxidative injury and after
damage. HA was added to some samples both at the moment of
injury and at every media change. (a) Cells damaged at 37°C for
30 min with hypoxanthine (2 mM) and xanthine oxidase (20–
60 mU); and (b) cells damaged at 37°C for 30 min with PMNs.
Each column depicts the mean value of three experiments. Values
are expressed as optical density (OD)±standard deviation (SD).
Fig. 7. HA-mediated recovery of chondrocyte viability when added
to cell culture only after oxidative damage. HA was absent from the
media culture at the moment of injury with oxygen-free radicals
(hypoxanthine and xanthine oxidase), and added to media culture
only after 30 min of chemical injury exposure. Each column depicts
the mean value of three experiments. Values are expressed as
optical density (OD)±standard deviation (SD).
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transmission electron microscope (Philips) at an accelerat-
ing voltage of 60 kV. Additional sections were also stained
with Toluidine blue and examined with light microscopy.
IMMUNOHISTOCHEMISTRY
Human chondrocytes were grown on glass coverslips,
fixed in acetone for 5 min and incubated with mouse
anti-human CD44 antibody in Tris–buffer saline (TBS:
10 mM Tris, 150 mM NaCl, pH 7.4). Coverslips were sub-
sequently treated with a secondary rabbit anti-mouse im-
munoglobulin (Dako) and then with APAAP (Dako). Lastly,
coverslips were stained with Fast red (Sigma) and counter-
stained with hematoxylin. Positive controls were obtained
using lymphocytes and negative controls, by using an
irrelevant mouse monoclonal primary antibody.
STATISTICAL ANALYSIS
Group data were expressed as mean±standard error.
Differences between groups were analyzed using the
Kruskal–Wallis test for viability data in the presence of
Hyalgan. This test for multiple comparisons was followed
by the Mann–Whitney U-test for comparison between
groups. Probability values of P<0.05 were considered as
significant. Data analysis was performed using the Stat
View SE Graphics Program (Abacus Concept Inc., Berkely,
CA, U.S.A.).
Results
HA AND CELL VIABILITY
Direct addition of HA was shown to increase normal
chondrocyte growth. As shown in Fig. 1, HA induced a
dose-dependent pro-proliferative effect up to 0.75 mg/ml,
with the greatest efficacy observed at 0.5 mg/ml. Statistical
analysis showed that growth enhancement was signifi-
cantly higher at the 0.5 mg/ml concentration than in cell
cultures without HA or with HA at higher (1 mg/ml) and
lower (0.25 mg/ml) concentrations (Kruskal–Wallis test for
multiple comparisons, P0.0205; and Mann–Whitney U
test for comparison between groups, P<0.05). At the high-
est concentration (1 mg/ml), HA demonstrated an opposite
effect, decreasing cell viability.
HA AND CD44 RECEPTOR
As shown in Fig. 2, immunohistochemical analysis dem-
onstrated that isolated chondrocytes used in the present
study highly expressed CD44 receptors. To verify whether
the mechanism of HA-enhanced cell proliferation was
mediated by the CD44 receptor, binding inhibition experi-
ments were performed using a specific anti-CD44 antibody.
In the presence of maximum competitive binding of the
CD44 receptor, HA had no effect on cell viability (Fig. 3).
This inhibition was statistically significant at 9 days of
culture (Mann–Whitney U test for comparison between
groups, P<0.05). Furthermore, in the absence of exog-
enous HA, addition of anti-CD44 antibodies to control cell
cultures at 9 days slightly, but significantly inhibited their
normal baseline proliferation (Mann–Whitney U test for
comparison between groups, P<0.05).
HA AND FREE-RADICAL DAMAGE
Light microscopy demonstrated xanthine oxidase- or
PMN-treated cells to have enhanced cytoplasmic vacuo-
lization and chromatin condensation, phenomena that are
known to be associated with oxidative damage (Fig. 4).
However, nuclear condensation of damaged chondrocytes
was more evident in the absence (panel b) than in the
presence (panel c) of HA. Ultrastructurally, damaged
chondrocytes appeared extensively altered, with marked
chromatin condensation and nuclear pyknosis. However,
HA-treated cells demonstrated a notable euchromatic
nuclear pattern (Fig. 5), even though cytoplasmic vacuo-
lization was present.
MTT viability tests showed that when HA was added to
cultures at the moment of chemical [Fig. 6(a)] or activated
PMN damage and at every change of media, cell viability
was enhanced. This effect was more significant when cell
cultures were maintained for 9–10 days [Fig. 6(a),(b)]. Cells
chemically damaged and treated with HA only after cell
injury, and subsequently at every change of media, also
showed enhanced chondrocyte viability (Fig. 7).
Discussion
This study explored the effects of HA on the viability of
normal and injured human chondrocytes. This primary
culture model has been standardized and proven to be
physiologically relevant, maintaining the phenotype of cells
over time. RT–PCR testing (data not shown) demonstrated
that these primary cultures of chondrocytes at second
passage expressed collagen type II (80%) and collagen
type I (20%), findings that verify the preservation of the
chondrocyte phenotype.
Results of this study demonstrated that 5–7×105 MW
HA-enhanced in vitro chondrocyte viability and attenuated
the oxidative injury and subsequent decreased survival of
these cells in primary culture. The 0.5 mg/ml concentration
was identified from the initial dose–response analysis to
significantly increase viability of cells in standard culture
conditions, whereas the 0.25 and 0.75 mg/ml doses only
slightly increased cell survival. Conversely, at 1 mg/ml, an
inhibitory effect of HA on the viability of cells in culture was
observed. This is in disagreement with the results of Ishida
et al.17, who found that HA was still stimulatory at the
1 mg/ml concentration. This discrepancy is probably due to
the different cell populations studied: in the present article,
human normal articular cartilage-derived chondrocytes
were used, while in the Ishida study, chondrosarcoma-
derived chondrocyte-like cells were used.
This study also showed that the effect of HA on cell
survival appeared to be mediated by the CD44 receptor.
This receptor activity was also shown in samples in which
no HA was added, demonstrating that the CD44 receptor
also mediates endogenous effects of HAs. These findings
are in agreement with several other recent studies, in which
the CD44 receptor was shown to mediate the effects of
HAs on cell proliferation and motility in normal and tumor
cells7,12–17,41–43.
Despite the confusion that still exists with respect to the
physiological role of HA and its receptors, and the influence
of MW on its pharmacological activity, it is clear that HA,
after binding to the cell surface, triggers a cascade of
cellular events, such as growth, differentiation, migration,
tumor progression and apoptosis44,45. HA also appears
to have an important role in scavenging oxygen
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radicals20,25,26,46 and this effect, again, varies with molecu-
lar mass and concentration25,47–49.
Human chondrocytes exposed to oxygen radical flux
underwent morphological and structural changes charac-
terized by cytoplasmic vacuolization and chromatin con-
densation. In the present study, the morphological changes
caused by oxidative injury were less pronounced when
cells were treated with HA at the moment of oxidative
damage, particularly with regard to the nuclear chromatin
structure. More importantly, HA treatment restored the
viability of cells damaged with xanthine oxidase or PMN
exposure. HA also protected to a similar extent against both
chemically generated and activated neutrophil-generated
oxidative injury. Activated neutrophils, in fact, are able
to release a number of oxidative agents, all potentially
involved in the induction of cellular damage50,51.
The present findings demonstrated that one protective
function of HA may be enhancement of cell survival. HA not
only increased viability of normal chondrocytes, but also
restored survival of cells damaged with hydroxyl radicals. In
fact, when HA was added to oxidative-stress damaged
cells, it restored cell viability to near baseline values,
demonstrating indirectly that HA stimulated cellular prolif-
eration. Moreover, HA exerted its beneficial effect both
when added to damaged cells at the moment and immedi-
ately after the oxidative damage (Fig. 6), and when added
only after injury (Fig. 7). The effect of HA may thus be due
to both a role in scavenging oxygen radicals, and an
enhancement of cell proliferation.
While the MTT test used in the present study may be
considered only an indirect measurement of cell prolifer-
ation, Beales found a good relationship between viability
measured by MTT and cell proliferation measured by
[H3] thymidine incorporation. Other researchers reached
the same conclusions comparing the BrdU assay and
MTT52–54.
In conclusion, these results demonstrated that the tested
HA preparation (Hyalgan) was able to enhance human
chondrocyte survival/proliferation after exposure to oxygen-
free radicals, and that this effect was mediated by the
CD44/HA pathway. This enhanced chondrocyte prolifer-
ation and survival under conditions of oxidative injury
may be one possible therapeutic mechanism of HA in
osteoarthritis.
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